MétaCan
Menu
Back to cohort
Record W4390143881 · doi:10.1002/mds.29691

Embedding Patient Input in Outcome Measures for Long‐Term Disease‐Modifying Parkinson Disease Trials

2023· article· en· W4390143881 on OpenAlexaff
Cristina Gonzalez‐Robles, Michèle Bartlett, Matthew Burnell, Caroline S. Clarke, Shlomi Haar, Brook Huxford, Ashwani Jha, Michael Lawton, Alastair J. Noyce, Paola Piccini, Kuhan Pushparatnam, Lynn Rochester, Carroll Siu, Daniel J. van Wamelen, Caroline H. Williams‐Gray, Marie‐Louise Zeissler, Henrik Zetterberg, Camille Carroll, Thomas Foltynie, Rimona S. Weil, Anette Schrag

Bibliographic record

VenueMovement Disorders · 2023
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsCentre for Movement Disorders
FundersNIHR Cambridge Biomedical Research CentreJohn Black Charitable FoundationUK Dementia Research InstituteH. Lundbeck A/SMoorfields Eye Hospital NHS Foundation TrustSiemens HealthineersNorges ForskningsrådNovo NordiskVetenskapsrådetEisaiHORIZON EUROPE Framework ProgrammeUniversity of BristolRosetrees TrustAsthma and Lung UKWellcome TrustUniversity College LondonParkinson's UKVoyager TherapeuticsNewcastle UniversityAstraZenecaBarts CharityProthenaEU Joint Programme – Neurodegenerative Disease ResearchEuropean Association of UrologyVan Andel Research InstituteApellis PharmaceuticalsHealth and Social Care Delivery ResearchMichael J. Fox Foundation for Parkinson's ResearchBoston Scientific CorporationAlzheimer's AssociationStiftelsen för Gamla TjänarinnorHjärnfondenEuropean CommissionFamiljen Erling-Perssons StiftelseNational Institute for Health and Care ResearchMedical Research CouncilSamsung Biomedical Research InstituteTeva Pharmaceutical IndustriesBiogenProgramme Grants for Applied ResearchCHDI FoundationResearch for Patient Benefit ProgrammeAlzheimer's Drug Discovery FoundationSanofi
KeywordsPhysical therapyRating scaleOutcome (game theory)DiseaseMovement disordersClinical trialParkinson's diseasePhysical medicine and rehabilitationPsychologyClinical endpointMedicineInternal medicine

Abstract

fetched live from OpenAlex

BACKGROUND: Clinical trials of disease-modifying therapies in PD require valid and responsive primary outcome measures that are relevant to patients. OBJECTIVES: The objective is to select a patient-centered primary outcome measure for disease-modification trials over three or more years. METHODS: Experts in Parkinson's disease (PD), statistics, and health economics and patient and public involvement and engagement (PPIE) representatives reviewed and discussed potential outcome measures. A larger PPIE group provided input on their key considerations for such an endpoint. Feasibility, clinimetric properties, and relevance to patients were assessed and synthesized. RESULTS: Although initial considerations favored the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III in Off, feasibility, PPIE input, and clinimetric properties supported the MDS-UPDRS Part II. However, PPIE input also highlighted the importance of nonmotor symptoms, especially in the longer term, leading to the selection of the MDS-UPDRS Parts I + II sum score. CONCLUSIONS: The MDS-UPDRS Parts I + II sum score was chosen as the primary outcome for large 3-year disease-modification trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.055
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.081
GPT teacher head0.359
Teacher spread0.278 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueMovement DisordersSame topicParkinson's Disease Mechanisms and TreatmentsFrench-language works237,207